This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pfizer To Present New Data In Lung And Kidney Cancers At The European Society For Medical Oncology 2012 Congress

About TORISEL ® (temsirolimus)

TORISEL ® is the only intravenous mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of advanced renal cell carcinoma (RCC).

TORISEL inhibits the activity of mTOR, an intracellular protein implicated in multiple growth-related cellular functions including proliferation, growth and survival. The inhibition of mTOR also reduces levels of certain growth factors, such as vascular endothelial growth factor (VEGF), which are overexpressed in solid tumors like kidney cancer and are thought to play a crucial role in angiogenesis, the process by which tumors acquire blood vessels, nutrients and oxygen needed for growth.

Important TORISEL ® (temsirolimus) Safety Information 15

Serious reactions observed with TORISEL are hypersensitivity/infusion reactions (including some life-threatening and rare fatal reactions), hyperglycaemia/glucose intolerance, infections, interstitial lung disease (pneumonitis), hyperlipaemia, intracerebral bleeding, renal failure, bowel perforation, and wound healing complication.

The most common (≥30%) adverse reactions (all grades) observed with TORISEL include anaemia, nausea, rash (including rash, pruritic rash, maculopapular rash, pustular rash), anorexia, oedema (including facial oedema and peripheral oedema), and asthenia.

Cataracts have been observed in some patients who received the combination of temsirolimus and interferon α.

For more information on XALKORI (crizotinib), INLYTA (axitinib), SUTENT (sunitinib malate) and TORISEL (temsirolimus), including full prescribing information, please visit www.pfizer.com.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time. For more information please visit www.Pfizer.com.

DISCLOSURE NOTICE:

The information contained in this release is as of September 17, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about various potential indications for dacomitinib, Xalkori (crizotinib) and INLYTA (axitinib), including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, (i) the uncertainties inherent in research and development; (ii) decisions by the FDA, the European Commission and regulatory authorities in other jurisdictions regarding whether and when to approve drug applications that have been or may be filed for any such indications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of any such indications; and (iii) competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

1 ESMO 2012 Accepted Late Breaking Abstract #LBA1. Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced, ALK-positive NSCLC (PROFILE 1007). Sunday, September 30: 16:00 CEST. A. Shaw - Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

2 ESMO Accepted Abstract #1230. Updated Results of a Global Phase II Study with Crizotinib in Advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC).Poster Discussion. Sunday, September 30: 13:00 CEST. D.W. Kim – Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

3 ESMO Accepted Abstract #1191. Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement. Poster Discussion. Sunday, September 30: 13:15 CEST. S.-H. I. Ou – Presenter. 37th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

4 ESMO Accepted Abstract #1228. Dacomitinib (PF-00299804), an Irreversible Pan-HER Tyrosine Kinase Inhibitor (TKI), for First-Line Treatment of EGFR-Mutant or HER2-Mutant or Amplified Lung Cancers. Proffered Paper. Sunday, September 30: 10:30 CEST. M. Kris – Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

5 ESMO Accepted Abstract #1290. Phase I Trial of Irreversible Pan-ERBB Inhibitor Dacomitinib (dac) in Combination with ALK/MET Inhibitor Crizotinib (criz) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). Poster Presentation. Saturday, September 29: 13:00 – 14:00. X.-C. Zhang – Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

6 ESMO Accepted Abstract #811. Clinic and Home Blood Pressure Measurements are Reliable for Guiding Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Axitinib as First-Line Therapy. Poster Presentation. Saturday, September 29: 13:00 – 14:00. V. Grünwald – Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

7 ESMO Accepted Abstract #793. Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors. Poster Discussion. Monday, October 1: 13:00 CEST. R. Motzer – Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

8 ESMO Accepted Abstract #785. Comparative Assessment of Sunitinib-Associated Adverse Events (AEs) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (mRCC). Proffered Paper. Monday, October 1: 15:15 CEST. F. Donskov – Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

9 ESMO Accepted Abstract #815. Sunitinib (SU) Dosing Schedule and Data Collection Timepoints: Impact on Quality of Life (QoL) Outcomes in Metastatic Renal Cell Carcinoma (mRCC). Poster Presentation. Saturday, September 29: 13:00-14:00 CEST. A. Bushmakin – Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

10 ESMO 2012 Accepted Late Breaking Abstract #LBA22_PR. Randomized Phase 3 trial of temsirolimus versus sorafenib as second-line therapy in metastatic RCC (mRCC): Results From the INTORSECT Trial. Monday, October 1: 14:00 – 15:50 CEST. Proffered Papers Session. T. Hutson - Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

11 ESMO 2012 Accepted Late Breaking Abstract #LBA21_PR. Randomized Phase 3b trial of temsirolimus and bevacizumab versus Interferon and bevacizumab in metastatic RCC: Results from INTORACT. Monday, October 1: 14:00 – 15:50 CEST. Proffered Papers Session. B. Rini - Presenter. 37 th Congress of the European Society for Medical Oncology. Vienna, Austria. September 28 – October 2, 2012.

12 XALKORI (crizotinib) Prescribing Information. Pfizer Inc, New York, NY. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s003lbl.pdf.

13 Summary of Product Characteristics for INLYTA ®. Sandwich, Kent: UK; 2012. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002406/WC500132188.pdf

14 Summary of Product Characteristics for SUTENT ®. Sandwich, Kent: UK; 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000687/WC500057737.pdf

15 Summary of Product Characteristics for TORISEL ®. Sandwich, Kent: UK; 2011. Available at: http://www.medicines.org.uk/emc/medicine/21260.

Copyright Business Wire 2010
5 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs